Study-context terms explain dose, route, formulation, timing, and endpoint.
Dictionary / Study context
Formulation
Product form, carrier, purity, and mixture details that affect evidence scope.
Study contextterm category
7related public pages
editorial navigationdefinition status
draftreview status
201exact evidence rows
168exact source links
139nearby evidence rows
139nearby source links
0do-not-confuse links
0entity links
This page is a dictionary definition and navigation aid. Exact evidence rows below come from approved workbench claims; broader claims and citations live on the related source-backed pages.
Dictionary Reader Map
Use the definition as a doorway, not a conclusion.
Formulation explains vocabulary used across the cannabinoid encyclopedia. The definition orients the reader; exact rows and related pages carry the source-backed claims.
168 direct sources linked to approved workbench claims. PubMed 39204082
139 nearby evidence rows and 139 nearby source links.
Aliases help readers find the same concept without changing the evidence standard.
Plain-Language Definition
What it means here
Formulation is used in this encyclopedia as a study context term. Product form, carrier, purity, and mixture details that affect evidence scope.
Study-context terms explain the conditions around a source: route, dose, formulation, timing, population, model, duration, and endpoint.
No common aliases are listed for this term yet.
Evidence Guardrail
How to read it without overreaching
Study context is the difference between a useful evidence row and an overread claim. Keep this term attached to the exact source, product, model, timing, and endpoint wherever possible.
Evidence Lens
What this term can currently point to
Direct approved claim rows linked to this dictionary term. PubMed 39204082
Distinct source records under those exact rows. PubMed 39204082
Source-backed public pages where this vocabulary is likely useful. Open related page
Evidence rows available on those related public pages. Open related page
Exact rows are direct evidence links. Use them first, then use related pages to understand the broader research context.
Source Path
How to move from this definition to research
- Read the definition.Use it to understand the vocabulary in plain English.
- Check exact rows.When direct rows exist, open the linked PubMed or DOI record. PubMed 39204082
- Open related pages.Use nearby pages for broader source-backed context. Related page
- Keep the boundary.Study context changes what a source can support, so keep it attached to the row.
Exact Evidence Rows
Approved source-backed rows linked to this term
201 exact rows
No matching evidence rows.
Evidence Group
Preliminary Human
39 exact rows / 30 sources
Evidence row 4 / uses term
CBN decreases Overall sleep disturbance.
preliminary human / low confidence.
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PubMed 39204082
Claim or source metadata contains an explicit term marker.
Evidence row 5 / uses term
CBN no detected effect on Side effect frequency.
preliminary human / low confidence.
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PubMed 39204082
Claim or source metadata contains an explicit term marker.
Evidence row 29 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. PubMed 35617670
Claim or source metadata contains an explicit term marker.
Evidence row 60 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Effect of Preoperative Oral Cannabidiol-Rich Cannabis Extract on Anxiety and Postoperative Pain after Endodontic Treatment: A Double-Blind Randomized Clinical Trial. PubMed 39505200
Claim or source metadata contains an explicit term marker.
Evidence row 62 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PubMed 39151115
Claim or source metadata contains an explicit term marker.
Evidence row 97 / uses term
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Adverse events associated with medical cannabis reported within a centralized call center. PubMed 42158949
Claim or source metadata contains an explicit term marker.
Evidence row 149 / uses term
CBN studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 155 / uses term
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Unintentional ingestion of putative delta-8 tetrahydrocannabinol by two youth requiring critical care: a case report. PubMed 36941718
Claim or source metadata contains an explicit term marker.
Evidence row 156 / uses term
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Using Large Language Models to Support Content Analysis: A Case Study of ChatGPT for Adverse Event Detection. PubMed 38696245
Claim or source metadata contains an explicit term marker.
Evidence row 159 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). PubMed 37947792
Claim or source metadata contains an explicit term marker.
Evidence row 162 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Safety study of cannabidiol products in healthy dogs. PubMed 38496308
Claim or source metadata contains an explicit term marker.
Evidence row 163 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. PubMed 42057192
Claim or source metadata contains an explicit term marker.
Evidence row 169 / uses term
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PubMed 37162192
Claim or source metadata contains an explicit term marker.
Evidence row 221 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
The contribution of addictovigilance data to the French medical cannabis experimentation. PubMed 39547825
Claim or source metadata contains an explicit term marker.
Evidence row 227 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability. PubMed 42204954
Claim or source metadata contains an explicit term marker.
Evidence row 233 / uses term
THC studied for Cannabinoids and nausea/vomiting research outcomes.
preliminary human / very_low confidence.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PubMed 39151115
Claim or source metadata contains an explicit term marker.
Evidence row 238 / uses term
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Adverse Effects of Recreational and Medical Cannabis. PubMed 33897066
Claim or source metadata contains an explicit term marker.
Evidence row 321 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. PubMed 26724101
Claim or source metadata contains an explicit term marker.
Evidence row 323 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. PubMed 29768152
Claim or source metadata contains an explicit term marker.
Evidence row 324 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. PubMed 28538134
Claim or source metadata contains an explicit term marker.
Evidence row 334 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Potency Analysis of Medical Marijuana Products from New York State. PubMed 31559335
Claim or source metadata contains an explicit term marker.
Evidence row 338 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabinoids in dermatology: a scoping review. PubMed 30142706
Claim or source metadata contains an explicit term marker.
Evidence row 350 / uses term
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Using Transformer-Based Topic Modeling to Examine Discussions of Delta-8 Tetrahydrocannabinol: Content Analysis. PubMed 38127427
Claim or source metadata contains an explicit term marker.
Evidence row 351 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
Derivation of a health-based guidance value for Δ8-tetrahydrocannabinol (Δ8-THC) and its occurrence in food. PubMed 41262681
Claim or source metadata contains an explicit term marker.
Evidence row 354 / uses term
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
preliminary human / very_low confidence.
[Not Available]. PubMed 39323250
Claim or source metadata contains an explicit term marker.
Evidence row 406 / uses term
CBD studied for Sleep.
preliminary human / very_low confidence.
Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. PubMed 39167421
Claim or source metadata contains an explicit term marker.
Evidence row 414 / uses term
CBD studied for Sleep.
preliminary human / very_low confidence.
Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial. PubMed 38758300
Claim or source metadata contains an explicit term marker.
Evidence row 433 / uses term
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study. PubMed 42261989
Claim or source metadata contains an explicit term marker.
Evidence row 482 / uses term
THC studied for Nausea and vomiting.
preliminary human / very_low confidence.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PubMed 39151115
Claim or source metadata contains an explicit term marker.
Evidence row 492 / uses term
THC studied for Appetite and metabolic outcomes.
preliminary human / very_low confidence.
Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. PubMed 16849753
Claim or source metadata contains an explicit term marker.
Evidence row 508 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 509 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 510 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. PubMed 39980821
Claim or source metadata contains an explicit term marker.
Evidence row 512 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PubMed 37162192
Claim or source metadata contains an explicit term marker.
Evidence row 544 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). PubMed 37947792
Claim or source metadata contains an explicit term marker.
Evidence row 546 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
Safety study of cannabidiol products in healthy dogs. PubMed 38496308
Claim or source metadata contains an explicit term marker.
Evidence row 637 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. PubMed 42057192
Claim or source metadata contains an explicit term marker.
Evidence row 641 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PubMed 37162192
Claim or source metadata contains an explicit term marker.
Evidence row 745 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preliminary human / very_low confidence.
A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. PubMed 37721990
Claim or source metadata contains an explicit term marker.
Evidence Group
Insufficient
116 exact rows / 102 sources
Evidence row 93 / uses term
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Pharmacologic treatment of fibromyalgia: an update. PubMed 41142233
Claim or source metadata contains an explicit term marker.
Evidence row 94 / uses term
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. PubMed 21845389
Claim or source metadata contains an explicit term marker.
Evidence row 95 / uses term
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis-based medicines for chronic neuropathic pain in adults. PubMed 41548880
Claim or source metadata contains an explicit term marker.
Evidence row 96 / uses term
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey. PubMed 40708053
Claim or source metadata contains an explicit term marker.
Evidence row 141 / uses term
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles. PubMed 32735381
Claim or source metadata contains an explicit term marker.
Evidence row 142 / uses term
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Phytochemical Analysis of the Methanolic Extract and Essential Oil from Leaves of Industrial Hemp Futura 75 Cultivar: Isolation of a New Cannabinoid Derivative and Biological Profile Using Computational Approaches. PubMed 35807623
Claim or source metadata contains an explicit term marker.
Evidence row 150 / uses term
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Self-reported adverse events associated with ∆8-Tetrahydrocannabinol (Delta-8-THC) Use. PubMed 37217977
Claim or source metadata contains an explicit term marker.
Evidence row 151 / uses term
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. PubMed 38868665
Claim or source metadata contains an explicit term marker.
Evidence row 152 / uses term
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review. PubMed 39805119
Claim or source metadata contains an explicit term marker.
Evidence row 153 / uses term
Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Prevalence of carboxy-Δ8-tetrahydrocannabiniol in antidoping samples. PubMed 38176407
Claim or source metadata contains an explicit term marker.
Evidence row 154 / uses term
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. PubMed 36742440
Claim or source metadata contains an explicit term marker.
Evidence row 158 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids in clinical practice. PubMed 11152013
Claim or source metadata contains an explicit term marker.
Evidence row 160 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. PubMed 40206058
Claim or source metadata contains an explicit term marker.
Evidence row 166 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
The Potential of Cannabichromene (CBC) as a Therapeutic Agent. PubMed 38777605
Claim or source metadata contains an explicit term marker.
Evidence row 167 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PubMed 40872492
Claim or source metadata contains an explicit term marker.
Evidence row 168 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PubMed 37630401
Claim or source metadata contains an explicit term marker.
Evidence row 170 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. PubMed 38229238
Claim or source metadata contains an explicit term marker.
Evidence row 173 / uses term
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
CBD, a precursor of THC in e-cigarettes. PubMed 33903673
Claim or source metadata contains an explicit term marker.
Evidence row 196 / uses term
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PubMed 30374683
Claim or source metadata contains an explicit term marker.
Evidence row 197 / uses term
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Update on Cannabidiol in Drug-Resistant Epilepsy. PubMed 39585547
Claim or source metadata contains an explicit term marker.
Evidence row 198 / uses term
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. PubMed 31802404
Claim or source metadata contains an explicit term marker.
Evidence row 199 / uses term
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. PubMed 33667843
Claim or source metadata contains an explicit term marker.
Evidence row 200 / uses term
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program. PubMed 37593907
Claim or source metadata contains an explicit term marker.
Evidence row 217 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PubMed 37648266
Claim or source metadata contains an explicit term marker.
Evidence row 218 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis Use and the Risk for Psychosis and Affective Disorders. PubMed 31647377
Claim or source metadata contains an explicit term marker.
Evidence row 219 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies. PubMed 42309106
Claim or source metadata contains an explicit term marker.
Evidence row 220 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis and psychiatric disorders. PubMed 20562767
Claim or source metadata contains an explicit term marker.
Evidence row 222 / uses term
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Role of cannabis in cardiovascular disorders. PubMed 28840009
Claim or source metadata contains an explicit term marker.
Evidence row 228 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Pharmacotherapies for cannabis use disorder. PubMed 41025421
Claim or source metadata contains an explicit term marker.
Evidence row 229 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Clinical management of cannabis withdrawal. PubMed 34791767
Claim or source metadata contains an explicit term marker.
Evidence row 230 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. PubMed 35510826
Claim or source metadata contains an explicit term marker.
Evidence row 231 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The differential effects of medicinal cannabis on mental health: A systematic review. PubMed 40186931
Claim or source metadata contains an explicit term marker.
Evidence row 232 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. PubMed 38562466
Claim or source metadata contains an explicit term marker.
Evidence row 237 / uses term
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids and monoaminergic system: implications for learning and memory. PubMed 39206116
Claim or source metadata contains an explicit term marker.
Evidence row 239 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Prenatal cannabinoid exposure and altered neurotransmission. PubMed 30771373
Claim or source metadata contains an explicit term marker.
Evidence row 240 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. PubMed 26858214
Claim or source metadata contains an explicit term marker.
Evidence row 241 / uses term
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Endocannabinoid signaling and long-term synaptic plasticity. PubMed 19575681
Claim or source metadata contains an explicit term marker.
Evidence row 242 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies. PubMed 42076122
Claim or source metadata contains an explicit term marker.
Evidence row 244 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
[Not all drugs are the same]. PubMed 23974649
Claim or source metadata contains an explicit term marker.
Evidence row 245 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Brands of Intoxicating Cannabis Products in Vape Shops: United States, 2023. PubMed 41324909
Claim or source metadata contains an explicit term marker.
Evidence row 315 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? PubMed 17005273
Claim or source metadata contains an explicit term marker.
Evidence row 316 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cardiovascular consequences of marijuana use. PubMed 12412838
Claim or source metadata contains an explicit term marker.
Evidence row 317 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. PubMed 39575727
Claim or source metadata contains an explicit term marker.
Evidence row 318 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis use and acute coronary syndrome. PubMed 30964363
Claim or source metadata contains an explicit term marker.
Evidence row 319 / uses term
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Endocannabinoids, blood pressure and the human heart. PubMed 18426501
Claim or source metadata contains an explicit term marker.
Evidence row 320 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PubMed 37648266
Claim or source metadata contains an explicit term marker.
Evidence row 325 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. PubMed 38940871
Claim or source metadata contains an explicit term marker.
Evidence row 326 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Statewide Variation in Cannabinoid Regulations. PubMed 36848540
Claim or source metadata contains an explicit term marker.
Evidence row 327 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis Contaminants Limit Pharmacological Use of Cannabidiol. PubMed 33013414
Claim or source metadata contains an explicit term marker.
Evidence row 328 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Pesticides and trace elements in cannabis: Analytical and environmental challenges and opportunities. PubMed 31471034
Claim or source metadata contains an explicit term marker.
Evidence row 329 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cautious Hope for Cannabidiol (CBD) in Rheumatology Care. PubMed 32144889
Claim or source metadata contains an explicit term marker.
Evidence row 330 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. PubMed 27683558
Claim or source metadata contains an explicit term marker.
Evidence row 331 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products. PubMed 35987236
Claim or source metadata contains an explicit term marker.
Evidence row 332 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabidiol Gummy Products: LC-MS/MS Assessment of Cannabinoid Concentrations. PubMed 40454463
Claim or source metadata contains an explicit term marker.
Evidence row 333 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Acid-Catalyzed Conversion of Cannabidiol to Tetrahydrocannabinols: En Route to Demystifying Manufacturing Processes and Controlling the Reaction Outcomes. PubMed 40250991
Claim or source metadata contains an explicit term marker.
Evidence row 335 / uses term
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8 tetrahydrocannabinol: a scoping review and commentary. PubMed 36710464
Claim or source metadata contains an explicit term marker.
Evidence row 336 / uses term
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The potential role of cannabinoids in dermatology. PubMed 31599175
Claim or source metadata contains an explicit term marker.
Evidence row 337 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis and the skin. PubMed 34785006
Claim or source metadata contains an explicit term marker.
Evidence row 339 / uses term
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids and Their Receptors in Skin Diseases. PubMed 38003712
Claim or source metadata contains an explicit term marker.
Evidence row 340 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science. PubMed 41008526
Claim or source metadata contains an explicit term marker.
Evidence row 341 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids. PubMed 33851375
Claim or source metadata contains an explicit term marker.
Evidence row 342 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Potential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors. PubMed 38904694
Claim or source metadata contains an explicit term marker.
Evidence row 343 / uses term
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation. PubMed 33909195
Claim or source metadata contains an explicit term marker.
Evidence row 344 / uses term
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. PubMed 30138623
Claim or source metadata contains an explicit term marker.
Evidence row 345 / uses term
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations. PubMed 36439142
Claim or source metadata contains an explicit term marker.
Evidence row 346 / uses term
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. PubMed 19608284
Claim or source metadata contains an explicit term marker.
Evidence row 348 / uses term
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. PubMed 36742440
Claim or source metadata contains an explicit term marker.
Evidence row 349 / uses term
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers. PubMed 38686923
Claim or source metadata contains an explicit term marker.
Evidence row 352 / uses term
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Delta-8 THC Retail Availability, Price, and Minimum Purchase Age. PubMed 36342930
Claim or source metadata contains an explicit term marker.
Evidence row 355 / uses term
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
A Survey Study of Individuals Using Hexahydrocannabinol Cannabis Products: Use Patterns and Perceived Effects. PubMed 37934167
Claim or source metadata contains an explicit term marker.
Evidence row 374 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
The Psychiatric Consequences of Cannabinoids. PubMed 29678279
Claim or source metadata contains an explicit term marker.
Evidence row 375 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Pharmacotherapies for cannabis dependence. PubMed 30687936
Claim or source metadata contains an explicit term marker.
Evidence row 376 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. PubMed 32271390
Claim or source metadata contains an explicit term marker.
Evidence row 513 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes. PubMed 38924151
Claim or source metadata contains an explicit term marker.
Evidence row 514 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
[Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences]. PubMed 27428345
Claim or source metadata contains an explicit term marker.
Evidence row 515 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research. PubMed 32053725
Claim or source metadata contains an explicit term marker.
Evidence row 516 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. PubMed 36228902
Claim or source metadata contains an explicit term marker.
Evidence row 541 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. PubMed 39598860
Claim or source metadata contains an explicit term marker.
Evidence row 543 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids in clinical practice. PubMed 11152013
Claim or source metadata contains an explicit term marker.
Evidence row 545 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. PubMed 40206058
Claim or source metadata contains an explicit term marker.
Evidence row 549 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice. PubMed 39699828
Claim or source metadata contains an explicit term marker.
Evidence row 551 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Non-psychotropic cannabinoids as inhibitors of TET1 protein. PubMed 35462234
Claim or source metadata contains an explicit term marker.
Evidence row 552 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis. PubMed 40326034
Claim or source metadata contains an explicit term marker.
Evidence row 553 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. PubMed 33562819
Claim or source metadata contains an explicit term marker.
Evidence row 555 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? PubMed 37414155
Claim or source metadata contains an explicit term marker.
Evidence row 557 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling. PubMed 36497400
Claim or source metadata contains an explicit term marker.
Evidence row 558 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects. PubMed 42352060
Claim or source metadata contains an explicit term marker.
Evidence row 559 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. PubMed 32628766
Claim or source metadata contains an explicit term marker.
Evidence row 638 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
The Potential of Cannabichromene (CBC) as a Therapeutic Agent. PubMed 38777605
Claim or source metadata contains an explicit term marker.
Evidence row 639 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PubMed 40872492
Claim or source metadata contains an explicit term marker.
Evidence row 640 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PubMed 37630401
Claim or source metadata contains an explicit term marker.
Evidence row 642 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. PubMed 38229238
Claim or source metadata contains an explicit term marker.
Evidence row 645 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
CBD, a precursor of THC in e-cigarettes. PubMed 33903673
Claim or source metadata contains an explicit term marker.
Evidence row 647 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? PubMed 37414155
Claim or source metadata contains an explicit term marker.
Evidence row 648 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects. PubMed 42352060
Claim or source metadata contains an explicit term marker.
Evidence row 649 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. PubMed 32628766
Claim or source metadata contains an explicit term marker.
Evidence row 650 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabis Vaping: Existing and Emerging Modalities, Chemistry, and Pulmonary Toxicology. PubMed 34622654
Claim or source metadata contains an explicit term marker.
Evidence row 652 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Pre-puberty cannabichromene exposure modulates reproductive function via alteration of spermatogenesis, steroidogenesis, and eNOS pathway metabolites. PubMed 37396845
Claim or source metadata contains an explicit term marker.
Evidence row 653 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Genotoxicity of selected cannabinoids in human lymphoblastoid TK6 cells. PubMed 39172143
Claim or source metadata contains an explicit term marker.
Evidence row 656 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
insufficient / very_low confidence.
Development and validation of a fit-for-purpose UHPLC-ESI-MS/MS method for the quantitation of cannabinoids in different matrices. PubMed 36854205
Claim or source metadata contains an explicit term marker.
Evidence row 672 / uses term
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Effect of Quantitative Structural Properties and Drug Formulation in Four Cannabinoids (Cannabidiol, Cannabigerol, Cannabichromene, and Cannabinol) on Their Lymphatic Transport after Enteral Administration in Rats. PubMed 40611782
Claim or source metadata contains an explicit term marker.
Evidence row 736 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. PubMed 40270953
Claim or source metadata contains an explicit term marker.
Evidence row 737 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Investigational cannabinoids in seizure disorders, what have we learned thus far? PubMed 29842819
Claim or source metadata contains an explicit term marker.
Evidence row 739 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant). PubMed 21740450
Claim or source metadata contains an explicit term marker.
Evidence row 741 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, Δ8-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry. PubMed 38862388
Claim or source metadata contains an explicit term marker.
Evidence row 742 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. PubMed 40872492
Claim or source metadata contains an explicit term marker.
Evidence row 743 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PubMed 37630401
Claim or source metadata contains an explicit term marker.
Evidence row 748 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing. PubMed 37697897
Claim or source metadata contains an explicit term marker.
Evidence row 749 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ8-tetrahydrocannabinol: case studies. PubMed 35799289
Claim or source metadata contains an explicit term marker.
Evidence row 750 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. PubMed 25542687
Claim or source metadata contains an explicit term marker.
Evidence row 753 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products. PubMed 40131178
Claim or source metadata contains an explicit term marker.
Evidence row 754 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents. PubMed 35303507
Claim or source metadata contains an explicit term marker.
Evidence row 756 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. PubMed 31549358
Claim or source metadata contains an explicit term marker.
Evidence row 757 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies. PubMed 36280497
Claim or source metadata contains an explicit term marker.
Evidence row 758 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath. PubMed 35585089
Claim or source metadata contains an explicit term marker.
Evidence row 759 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
insufficient / very_low confidence.
Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PubMed 23894589
Claim or source metadata contains an explicit term marker.
Evidence Group
Preclinical
15 exact rows / 11 sources
Evidence row 171 / uses term
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preclinical / very_low confidence.
Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. PubMed 40580638
Claim or source metadata contains an explicit term marker.
Evidence row 172 / uses term
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preclinical / very_low confidence.
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PubMed 37721989
Claim or source metadata contains an explicit term marker.
Evidence row 174 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preclinical / very_low confidence.
The antinociceptive activity and mechanism of action of cannabigerol. PubMed 36916438
Claim or source metadata contains an explicit term marker.
Evidence row 223 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
preclinical / very_low confidence.
Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. PubMed 36603937
Claim or source metadata contains an explicit term marker.
Evidence row 353 / uses term
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
preclinical / very_low confidence.
Hexahydrocannabinol: pharmacokinetics, systemic toxicity, and acute behavioral effects in Wistar rats. PubMed 40643195
Claim or source metadata contains an explicit term marker.
Evidence row 356 / uses term
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
preclinical / very_low confidence.
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice. PubMed 40176500
Claim or source metadata contains an explicit term marker.
Evidence row 550 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
Cannabigerol does not affect contextual fear memory in mice but modulates nociception in a sex-dependent manner. PubMed 40523564
Claim or source metadata contains an explicit term marker.
Evidence row 598 / uses term
CBG studied for Inflammation-related outcomes.
preclinical / very_low confidence.
High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model. PubMed 39009468
Claim or source metadata contains an explicit term marker.
Evidence row 602 / uses term
CBG studied for Inflammation-related outcomes.
preclinical / very_low confidence.
Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model. PubMed 40943856
Claim or source metadata contains an explicit term marker.
Evidence row 628 / uses term
CBG studied for Appetite and metabolic outcomes.
preclinical / very_low confidence.
A cannabigerol-rich Cannabis sativa extract, devoid of [INCREMENT]9-tetrahydrocannabinol, elicits hyperphagia in rats. PubMed 28125508
Claim or source metadata contains an explicit term marker.
Evidence row 643 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. PubMed 40580638
Claim or source metadata contains an explicit term marker.
Evidence row 644 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PubMed 37721989
Claim or source metadata contains an explicit term marker.
Evidence row 646 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
The antinociceptive activity and mechanism of action of cannabigerol. PubMed 36916438
Claim or source metadata contains an explicit term marker.
Evidence row 744 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preclinical / very_low confidence.
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PubMed 37721989
Claim or source metadata contains an explicit term marker.
Evidence row 747 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preclinical / very_low confidence.
Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain. PubMed 42151379
Claim or source metadata contains an explicit term marker.
Evidence Group
Mechanistic or Pharmacological
31 exact rows / 25 sources
Evidence row 157 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. PubMed 39596290
Claim or source metadata contains an explicit term marker.
Evidence row 161 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. PubMed 42163693
Claim or source metadata contains an explicit term marker.
Evidence row 164 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. PubMed 39004335
Claim or source metadata contains an explicit term marker.
Evidence row 165 / uses term
CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. PubMed 41822224
Claim or source metadata contains an explicit term marker.
Evidence row 216 / uses term
THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms.
mechanistic or pharmacological / very_low confidence.
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PubMed 27498155
Claim or source metadata contains an explicit term marker.
Evidence row 243 / uses term
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Hexahydrocannabinol-induced rhabdomyolysis and acute kidney injury: a case report combining comprehensive toxicokinetic and metabolomic investigations. PubMed 42106886
Claim or source metadata contains an explicit term marker.
Evidence row 322 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Cannabinoid treatment for autism: a proof-of-concept randomized trial. PubMed 33536055
Claim or source metadata contains an explicit term marker.
Evidence row 347 / uses term
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model. PubMed 31350927
Claim or source metadata contains an explicit term marker.
Evidence row 511 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. PubMed 39004335
Claim or source metadata contains an explicit term marker.
Evidence row 542 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. PubMed 39596290
Claim or source metadata contains an explicit term marker.
Evidence row 547 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Safety assessment and redox status in rats after chronic exposure to cannabidiol and cannabigerol. PubMed 36796712
Claim or source metadata contains an explicit term marker.
Evidence row 548 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities. PubMed 40540228
Claim or source metadata contains an explicit term marker.
Evidence row 554 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Could cannabigerol protect against neuroinflammation? Insights from an in vitro microglial study. PubMed 41548647
Claim or source metadata contains an explicit term marker.
Evidence row 556 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
The impact of cannabigerol exposure on human endometrial stromal cells decidualization. PubMed 42107483
Claim or source metadata contains an explicit term marker.
Evidence row 560 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues. PubMed 36272108
Claim or source metadata contains an explicit term marker.
Evidence row 561 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models. PubMed 41934896
Claim or source metadata contains an explicit term marker.
Evidence row 562 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. PubMed 35246858
Claim or source metadata contains an explicit term marker.
Evidence row 636 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. PubMed 42163693
Claim or source metadata contains an explicit term marker.
Evidence row 651 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs. PubMed 33134364
Claim or source metadata contains an explicit term marker.
Evidence row 654 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. PubMed 20619971
Claim or source metadata contains an explicit term marker.
Evidence row 655 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Mapping the research landscape of minor cannabinoids: a bibliometric analysis of research trends and hotspots. PubMed 41668212
Claim or source metadata contains an explicit term marker.
Evidence row 738 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. PubMed 27573936
Claim or source metadata contains an explicit term marker.
Evidence row 740 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity. PubMed 42196303
Claim or source metadata contains an explicit term marker.
Evidence row 746 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption. PubMed 41947574
Claim or source metadata contains an explicit term marker.
Evidence row 751 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. PubMed 26577065
Claim or source metadata contains an explicit term marker.
Evidence row 752 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Hair Regrowth with Novel Hemp Extract: A Case Series. PubMed 37305187
Claim or source metadata contains an explicit term marker.
Evidence row 755 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. PubMed 23712280
Claim or source metadata contains an explicit term marker.
Evidence row 764 / uses term
THCV modulates receptor, target, metabolic, or pharmacology mechanisms.
mechanistic or pharmacological / very_low confidence.
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PubMed 27498155
Claim or source metadata contains an explicit term marker.
Evidence row 784 / uses term
THCV studied for Inflammation-related outcomes.
mechanistic or pharmacological / very_low confidence.
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PubMed 27498155
Claim or source metadata contains an explicit term marker.
Evidence row 1006 / uses term
THCV modulates TRPV3.
mechanistic or pharmacological / very_low confidence.
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. PubMed 27498155
Claim or source metadata contains an explicit term marker.
Evidence row 1159 / uses term
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms.
mechanistic or pharmacological / very_low confidence.
Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. PubMed 18806815
Claim or source metadata contains an explicit term marker.
Source-Backed Connections
Related pages in the current encyclopedia
safety
Product contamination and formulation risk
12 evidence rows / 12 sources
topic
Cannabinoid product contamination and formulation risk review
12 evidence rows / 12 sources
topic
Commercial and semi-synthetic cannabinoids safety review
12 evidence rows / 12 sources
topic
Minor cannabinoids safety surveillance map
36 evidence rows / 36 sources
topic
THCV and safety/tolerability research summary
24 evidence rows / 24 sources
topic
CBG and safety/tolerability research summary
22 evidence rows / 22 sources
topic
CBC and safety/tolerability research summary
21 evidence rows / 21 sources
Nearby Terms